click below
click below
Normal Size Small Size show me how
GI Disorders
Med Chem
| Drug | Clinically relevant PK/PD | ADMET | Inactivation | Pharmacophore | Stimuli | Moeity | Analogs |
|---|---|---|---|---|---|---|---|
| Omeprazole | OBA decreases with food; take ≥30 min before meals | Metabolism: CYP2C19, CYP3A4; counsel calcium if long-term use. | enteric-coated to avoid pre-systemic acid inactivation | 2-pyridylmethylsulfinylbenzimidazole | Acid secretion is stimulated by gastrin, acetylcholine, histamine (context for target). | Substituted benzimidazole resemble imidazoles that bind CYP heme iron | R enantiomer has greater AUC |
| Esomeprazole | OBA decreases with food; take ≥30 min before meals | Metabolism: CYP2C19, CYP3A4; counsel calcium if long-term use. | enteric-coated to avoid pre-systemic acid inactivation | 2-pyridylmethylsulfinylbenzimidazole | Acid secretion is stimulated by gastrin, acetylcholine, histamine (context for target). | Substituted benzimidazole resemble imidazoles that bind CYP heme iron | S (-) enantiomer |
| Lansoprazole | OBA decreases with food; take ≥30 min before meals | Metabolism: CYP2C19, CYP3A4; counsel calcium if long-term use. | enteric-coated to avoid pre-systemic acid inactivation | 2-pyridylmethylsulfinylbenzimidazole | Acid secretion is stimulated by gastrin, acetylcholine, histamine (context for target). | Substituted benzimidazole resemble imidazoles that bind CYP heme iron | Class analogs listed together |
| Dexlansoprazole | OBA decreases with food; take ≥30 min before meals | Metabolism: CYP2C19, CYP3A4; counsel calcium if long-term use. | enteric-coated to avoid pre-systemic acid inactivation | 2-pyridylmethylsulfinylbenzimidazole | Acid secretion is stimulated by gastrin, acetylcholine, histamine (context for target). | Substituted benzimidazole resemble imidazoles that bind CYP heme iron | R (+) enantiomer, greater AUC |
| Pantoprazole | OBA decreases with food; take ≥30 min before meals | Metabolism: CYP2C19, CYP3A4; counsel calcium if long-term use. | enteric-coated to avoid pre-systemic acid inactivation | 2-pyridylmethylsulfinylbenzimidazole | Acid secretion is stimulated by gastrin, acetylcholine, histamine (context for target). | Substituted benzimidazole resemble imidazoles that bind CYP heme iron | Class analogs listed together |
| Rabeprazole | OBA decreases with food; take ≥30 min before meals | Metabolism: CYP2C19, CYP3A4; counsel calcium if long-term use. | enteric-coated to avoid pre-systemic acid inactivation | 2-pyridylmethylsulfinylbenzimidazole | Acid secretion is stimulated by gastrin, acetylcholine, histamine (context for target). | Substituted benzimidazole resemble imidazoles that bind CYP heme iron | Class analogs listed together |
| Vonoprazan | dose-dependent ionic binding to H+ | Acid secretion is stimulated by gastrin, acetylcholine, histamine | |||||
| Cimetidine | Oral BA ~50%; mainly excreted renal+hepatic | Minimal metabolic transformation; largely unchanged with minor inactive metabolites; renal+hepatic excretion. | Substituted aromatic ring separated from a polar, non-ionizable group by an ethylthiomethyl chain | Histamine is the stimulus for H2-mediated acid secretion | Imidazole ring | ||
| Famotidine | Oral BA ~50%; mainly excreted renal+hepatic | Substituted aromatic ring separated from a polar, non-ionizable group by an ethylthiomethyl chain | Histamine is the stimulus for H2-mediated acid secretion | Imidazole ring | |||
| Ranitidine | NDMA impurity concerns; NDMA is hepatotoxic/carcinogenic; withdrawal in April 2020; later references to reformulation in lecture. | Substituted aromatic ring separated from a polar, non-ionizable group by an ethylthiomethyl chain | Histamine is the stimulus for H2-mediated acid secretion | Imidazole ring | |||
| Misoprostol | Orally active; inhibits acid secretion; stimulates mucus and bicarbonate. | Rapid metabolic inactivation avoided by structural changes at C-16; Abortifacient warning. | mimics PGE, PGI2 | Prostaglandins act as inhibitors of acid secretion | |||
| Sucralfate | Reacts with gastric HCl to form viscous, paste-like barrier; binds albumin/fibrinogen on ulcers; prevents back-diffusion of H+; adsorbs pepsin and bile acids. | Aluminum salt of sulfated sucrose | |||||
| Bismuth subsalicylate | Rapid dissociation in stomach; salicylate absorbed | bismuth eliminated in feces | Bismuth salt | ||||
| Aluminum hydroxide | OH- neutralizes gastric H+; Al3+ contributes to protective coating | Often combined with Mg(OH)2 (Maalox®, Gelusil®, Mylanta®) | |||||
| Magnesium hydroxide | OH- neutralizes gastric H+; Mg2+ contributes to protective coating | Often combined with Al(OH)3 | |||||
| Calcium carbonate | carbonate may stimulate gastrin → possible acid rebound | ||||||
| Sodium bicarbonate | |||||||
| Metoclopramide | dopamine | ||||||
| Palonosetron | Less effect on QTc; longer half-life (40 hrs), effective for delayed CINV | IV; long duration | Serotonin (enterochromaffin cells) | Ondansetron, granisetron, dolasetron | |||
| Aprepitant | t1/2 ~9 h; requires redosing on subsequent days for highly emetogenic chemo | Oral; CNS penetration | Morpholine-containing (class) | Substance P | Fosaprepitant (IV prodrug) | ||
| Rolapitant | Very long t1/2 ~7 days → dose once per cycle | Oral; IV formulation withdrawn in US due to anaphylaxis risk | — | Substance P | Aprepitant | ||
| Netupitant | Moderate CYP3A4 inhibitor; used with palonosetron | Oral (combo Akynzeo) | — | Substance P | Fosnetupitant (IV prodrug) | ||
| Droperidol | Rapid onset; short procedures; strong antiemetic potency | Requires EKG monitoring | Butyrophenone core | Dopamine | Haloperidol | ||
| Olanzapine | Sedation prominent first days; useful for breakthrough NV | Oral; crosses BBB | Thienobenzodiazepine | Dopamine/serotonin mediated | — |